4.7 Article

Chronic treatments with a 5-HT4 receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimer's disease

Journal

NEUROPHARMACOLOGY
Volume 126, Issue -, Pages 128-141

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuropharm.2017.08.031

Keywords

5-HT4 receptor agonist; Alzheimer's disease; Memory impairments; Olfactory tubing maze; Transgenic mouse model; Pharmacotherapy

Funding

  1. CNRS
  2. Aix-Marseille Universite
  3. French National Agency for Research [MAD5 ANR-15-CE16-0006, PREVENTAD ANR-11-MALZ-0007]
  4. A*MIDEX
  5. A*MIDEX - Investissements d'Avenir French Government [ANR-11-IDEX-0001-02]
  6. France Alzheimer
  7. La Fondation Vaincre Alzheimer [14776, 13745]
  8. University of Montpellier
  9. French National Agency of Research [ADAMGUARD ANR-12-BSV4-0008]
  10. France Alzheimer and La Fondation Vaincre Alzheimer [12721]
  11. French Fondation Plan Alzheimer
  12. LABEX A*MIDEX Management des Talents from Aix Marseille Universite
  13. Inserm

Ask authors/readers for more resources

Alzheimer's disease (AD) is the main cause of dementia and a major health issue worldwide. The complexity of the pathology continues to challenge its comprehension and the implementation of effective treatments. In the last decade, a number of possible targets of intervention have been pointed out, among which the stimulation of 5-HT4 receptors (5-HT(4)Rs) seems very promising. 5-HT4R agonists exert pro-cognitive effects, inhibit amyloid-beta peptide (A beta) production and therefore directly and positively impact AD progression. In the present work, we investigated the effects of RS 67333, a partial 5-HT4R agonist, after chronic administration in the 5xFAD mouse model of AD. 5xFAD male mice and their wild type (WT) male littermates received either RS 67333 or vehicle solution i.p., twice a week, for 2 or 4 months. Cognitive performance was evaluated in a hippocampal-dependent behavioral task, the olfactory tubing maze (OTM). Mice were then sacrificed to evaluate the metabolism of the amyloid precursor protein (APP), amyloidosis and neuroinflammatory processes. No beneficial effects of RS 67333 were observed in 5xFAD mice after 2 months of treatment, while 5xFAD mice treated for 4 months showed better cognitive abilities compared to vehicle-treated 5xFAD mice. The beneficial effects of RS 67333 on learning and memory correlated with the decrease in both amyloid plaque load and neuroinflammation, more specifically in the entorhinal cortex. The most significant improvements in learning and memory and reduction of pathology stigmata were observed after the 4-month administration of RS 67333, demonstrating that treatment duration is important to alleviate amyloidosis and glial reactivity, particularly in the entorhinal cortex. These results confirm the 5-HT4R as a promising target for AD pathogenesis and highlight the need for further investigations to characterize fully the underlying mechanisms of action. (C) 2017 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available